# A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC

> **NCT04803539** · PHASE2,PHASE3 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 260 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** capecitabine + camrelizumab + apatinib

## Key facts

- **NCT ID:** NCT04803539
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-01
- **Primary completion:** 2028-09-01
- **Final completion:** 2033-09-01
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2023-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04803539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04803539, "A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT04803539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*